Literature DB >> 3319143

Correlative studies on antigenicity of pancreatic cancer and blood group types.

E Uchida1, M A Tempero, D A Burnett, Z Steplewski, P M Pour.   

Abstract

Blood group-related antigenicity in 14 pancreatic cancer patients was examined by immunohistological method using monoclonal antibodies (MoAbs) against A, B, H, Lea, Leb, and CA 19-9 and compared with the phenotypic expression of the individuals' blood groups. MoAb-A reacted strongly with tumor tissue in four of five blood group A patients. Two of two patients with blood type B showed a weak, focal reactivity of their cancer with MoAb-B. H antigen was found in four of five patients from blood group A, while it was present in only one blood group O person and absent in B-type individuals. B antigen was inappropriately expressed in one person with type A blood and in two with type O. Lea antigen was expressed in all but two tumor tissues and Leb antigen in all tumorous tissues, irrespective of Le blood group status. MoAb 19-9 reacted with 11 of 14 cases.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3319143

Source DB:  PubMed          Journal:  Cancer Detect Prev Suppl        ISSN: 1043-6995


  6 in total

1.  ABO blood groups and cancer of the pancreas.

Authors:  V Annese; M Minervini; A Gabbrielli; G Gambassi; R Manna
Journal:  Int J Pancreatol       Date:  1990-03

2.  Comparative studies on the expression of gastrointestinal-cancer-associated antigen, PA8-15, CA19-9 and the blood-group antigens in non-malignant and malignant human pancreatic tissues.

Authors:  H Egami; K Sakamoto; R Yoshimura; M Arai; Y Takiyama; P M Pour
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

3.  Comparative studies on expression of CA 19-9 and DU-PAN-2 in pancreatic cancer tissue.

Authors:  H Takasaki; E Uchida; M A Tempero; D A Burnett; R S Metzgar; P M Pour
Journal:  Int J Pancreatol       Date:  1987 Oct-Dec

4.  ABO blood group and the risk of pancreatic cancer.

Authors:  Brian M Wolpin; Andrew T Chan; Patricia Hartge; Stephen J Chanock; Peter Kraft; David J Hunter; Edward L Giovannucci; Charles S Fuchs
Journal:  J Natl Cancer Inst       Date:  2009-03-10       Impact factor: 13.506

Review 5.  The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates.

Authors:  Katherine E Poruk; D Z Gay; K Brown; J D Mulvihill; K M Boucher; C L Scaife; M A Firpo; S J Mulvihill
Journal:  Curr Mol Med       Date:  2013-03       Impact factor: 2.222

6.  ABO Blood Type and the Long-term Outcomes of Pancreatic Cancer.

Authors:  Yoshinori Tanaka; Teru Kumagi; Takashi Terao; Taira Kuroda; Tomoyuki Yokota; Nobuaki Azemoto; Yoshiki Imamura; Kazuhiro Uesugi; Yoshiyasu Kisaka; Naozumi Shibata; Mitsuhito Koizumi; Yoshinori Ohno; Kozue Kanemitsu; Atsushi Yukimoto; Kazuhiro Tange; Mari Nishiyama; Teruki Miyake; Hideki Miyata; Hiroshi Ishii; Masanori Abe; Yoichi Hiasa
Journal:  Intern Med       Date:  2020-03-15       Impact factor: 1.271

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.